The ACR has developed two new clinical guidance documents for pediatric patients in the context of the COVID-19 pandemic, including for the care of children with pediatric rheumatic disease, and for the management of inflammatory syndromes in children with recent or concurrent infections with SARS-CoV-2, specifically Multisystem Inflammatory Syndrome in Children (MIS-C) and hyperinflammation during COVID-19.
You Might Also Like
Also By This Author
The recommendations for pediatric rheumatology patients address various treatment options and provide general guidance, as well as direction for when to start, stop, or reduce medications. For MIS-C, the recommendations focus on general guidance, diagnostic evaluation and therapy options, as well as comparing and contrasting the features of MIS-C and Kawasaki Disease. For hyperinflammation in COVID-19, the recommendations also focus on general guidance, as well as immunomodulatory treatment.
All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.